Outsourcing in Clinical Trials (OCT): Medical Devices Europe 2022
Date/TimeDate(s) - April 5, 2022 - April 6, 2022 All Day
LocationHilton Munich Airport
Terminalstraße Mitte 20
85356 München-Flughafen ,
Join NAMSA 5-6 April in Munich, Germany for Outsourcing in Clinical Trials: Medical Devices Europe. This conference will explore the latest regulatory updates, global clinical trials, advanced technologies and more. With presentations and panel discussions on the top industry trends and outsourcing challenges, and global medtech professionals gathering from around the globe, this two-day event provides an opportune learning and networking experience.
NAMSA EDUCATION SESSION
The Medical Device Regulation (2017/745) (MDR) in a Clinical Nutshell
Presented by Stefaan Van der Meulen; AVP of Global Clinical Business Development
5 April 2022 | 10:00-10:30 AM CEST
Description: There has been significant evolution in the European regulatory landscape over the past 10–15 years, particularly with respect to requirements for clinical evaluation. During this session, Stefaan Van der Meulen will discuss a few of the implications of MDR on clinical investigations.
NAMSA’s medical device experts will be available on-site for consultations. We welcome the opportunity to discuss the various pathways to market and suggestions on how to most efficiently and cost-effectively achieve market success based on your unique project objectives. Please contact us to reserve your consultation time.
Stefaan Van der MeulenAVP of Global Clinical Business Development
Based outside Ghent, Belgium, Stefaan Van der Meulen heads the Global Clinical Business Development team for NAMSA. Prior to this, he was leading the Syntactx offices in Europe as a Managing Partner also overseeing business development for the company on a global scale.
Stefaan began his career in the pharmaceutical industry working on early- and late-phase clinical research studies of various sizes and indications. While working at Novartis, he was a global co-driver for their risk-based monitoring initiative, a best practice that was also applied at Syntactx. At Cordis, a medical device developer and manufacturer, Stefaan concentrated on first-in-human and pivotal studies before transitioning to Core Laboratory and product specialist activities. He also has experience in product life-cycle development from both a clinical and marketing perspective.
Stefaan holds a Master of Biomedical Sciences from Ghent University in Belgium. He is fluent in Dutch, English and French, and proficient in Italian and German.